Skip to main content
SpringerLink
Log in

Nicergolin

  • Chapter
Neuro-Psychopharmaka Ein Therapie-Handbuch

  • 88 Accesses

Zusammenfassung

Auf der Suche nach einem Ergot-Alkaloid mit ausgeprägt blockierender Wirkung auf alpha-adrenerge Rezeptoren wurde in den 60er Jahren das halbsynthetische Ergolinderivat Nicergolin entwickelt. Dem damaligen Verständnis der Ätiologie dementieller Erkrankungen folgend, konzentrierten sich pharmakologische Untersuchungen auf vasodilatatorische Effekte, die aus der alpha-1rezeptorblockierenden Wirkung der Substanz resultieren: Neben zahlreichen tierexperimentellen Studien (Le Poncin-Lafitte et al. 1984) wiesen auch Untersuchungen am Menschen eine Verbesserung der durchschnittlichen zerebralen Hemisphären-Durchblutung nach (Iliff et al. 1979). Weitere Untersuchungen offenbarten jedoch pharmakologische Effekte, welche als die eigentlichen Hauptwirkungen der Substanz angesehen werden und unabhängig von der ebenfalls bewirkten Zunahme der zerebralen Durchblutung sind; sie sind auch unter den Bedingungen der Hyperkapnie und somit maximalen Gefäßdilatation nachweisbar (Boismare und Lorenzo 1975).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 64.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Aliprandi G v, Tantalo V (1979) Physiopathologie des Innenohres und Therapie der Perzeptionstaubheit. Arzneimittelforschung/Drug Res 29: 1287–1295

    CAS  Google Scholar 

  • Arcamone F, Glässer AG, Grafnetterova J, Minghetti A, Nicolella V (1972) Studies on the metabolism of ergoline derivatives. Metabolism of nicergoline in man and in animals. Biochem Pharmacol 21: 2205–2213

    Article  PubMed  CAS  Google Scholar 

  • Arnold JD (1977) Unveröffentlichte Archivdaten (Farmitalia, Freiburg, Deutschland)

    Google Scholar 

  • Arrigo A, Moglia A, Borsotti L, Massarini M, Alfonsi E, Battaglia A, Saccetti GA (1982) Double-blind, placebo-controlled, crossover trial with nicergoline in patients with senile dementia. Int J Clin Pharm Res [Suppl 1] 2: 33–41

    Google Scholar 

  • Battaglia A, Bruni G, Ardia A, Sacchetti G (1989) Nicergoline in mild to moderate dementia. A multicenter, double-blind, placebocontrolled study. Jags 37: 295–302

    CAS  Google Scholar 

  • Battaglia A, Annonik G, Pamparana F et al. (1995) Nicergoline in the long-term treatment of mild or moderate senile dementia. ECNP Congress, Venice, p 383

    Google Scholar 

  • Benzi G, De Bernardi M, Manzo L, Ferrara A, Pancheri P, Arrigoni E, Berte F (1972) Effect of lysergide and nicergoline on glucose metabolism investigated on the dog brain isolated in situ. J Pharm Sci 61, N 3: 348–352

    Article  PubMed  CAS  Google Scholar 

  • Benzi G, Arrigoni E, Pastoris O, Villa RF, Dagani F, Marzatico F, Agnoli A (1979) Effect of some drugs on cerebral energy state during and after hypoxia and complete or incomplete ischemia. Biochem Pharmacol 28: 435–439

    Article  PubMed  CAS  Google Scholar 

  • Beyer HH (1980) Die Verwendung von Nicergolin (Sermion®) bei Tinnitus aurium. Therapiewoche 30: 935–938

    Google Scholar 

  • Bianchine JR (1983) Unveröffentlichte Archivdaten (Farmitalia, Freiburg, Deutschland)

    Google Scholar 

  • Boismare F, Lorenzo J (1975) Study of the protection afforded by nicergoline against the effects of cerebral ischemia in the cat. Arzneimittelforschung/Drug Res 25: 410–413

    CAS  Google Scholar 

  • Bolli R, Ware JA, Brandon TA, Weilbaecher DG, Mace ML (1984) Platelet-mediated thrombosis in stenosed canine coronary arteries: inhibition by nicergoline, a platelet-active alphaadrenergic antagonist. J Am Coll Cardiol 3: 1417–1426

    Article  PubMed  CAS  Google Scholar 

  • Borromei A (1989) Adjuvant therapy for Parkinson’s disease. Preliminary data of a multicentre study with nicergoline. Funct Neurol 4: 63–67

    Google Scholar 

  • Cattabeni F (1996) Protein kinase C in synaptic plasticity: a molecular traget in the treatment of congnitive disorders. 4th Int Nice/Springfield Symposium, Nice

    Google Scholar 

  • Chandra P, Paul A (1985) The effects of nicergoline and other vaso-active substances on molecular biological processes in the brain and their effects on the learning abilities of rats. In: Heidrich H (ed) Proof of therapeutical effectiveness of nootropic and vasoactive drugs. Springer, Berlin Heidelberg New York Tokyo, pp 119–130

    Google Scholar 

  • De Agopian P, Rosa A, Gautier JC, Lhermitte F (1973) Thromboses arteriélles expêrimentales. Effect d’un alpha-bloquant: la nicergoline. Nouv Presse Med 2: 2521–2524

    Google Scholar 

  • Dolce G, Zamponi A, Cecconi V, Pola P (1984) Clinicical and EEG assessment of neurodynamic effect of nicergoline in cerebral functions recovery after brain hemisphere lesions. Proceedings, 14th C.I.N.P. Congress, Florence, June 23

    Google Scholar 

  • Dolce G, Cecconi V, Zamponi A, Zylbergmann R, Maggi L, Battaglia A (1985) Terapia farmacologica associata a riabilitazione neuromotoria nel paziente: un nuovo approccio metodologica per la valutazione clinica di farmaci nootropi. Giorn Geront [Suppl] 62: 55–63

    Google Scholar 

  • Domzat T, Tutaj A, Zydecka B (1989) Nicergoline in the treatment of ischaemic cerebral stroke. Funct Neurol 4: 131–133

    Google Scholar 

  • Ehrly AM, Lardgraf H (1985) Einfluß von Nicergolin auf die Filtrabilität hyperosmolaren Blutes. In: Heidrich H (Hrsg) Therapeutische Wirksamkeitsnachweise bei nootropen und vasoaktiven Substanzen: Fortschritte in der klinischen und experimentellen Nicergolin-Forschung. Springer, Berlin Heidelberg New York Tokyo, S 189 ff

    Google Scholar 

  • Fabbrini G, Martucci N, Battaglia A, Novellini R (1989) Nicergoline as a possible dopaminergic agent. Effects of serum prolactin levels. XIVth World Congress on Neurology, New Delhi, October 1989

    Google Scholar 

  • Fariello RG, Carfagna N (1991) Biological basis for synergism between pharmacological and behavioural intervention in the aging brain. Geriatria y Gerontologia 26 [Suppl 1]: 33

    Google Scholar 

  • Farmitalia Carlo Erba (1984) Plasma and brain levels of nicergoline and its metabolites in the rat. Confidential report 67l4/818i, June 1984

    Google Scholar 

  • Farmitalia Carlo Erba (1988) Comparative study of the bioavailability of three oral preparations of nicergoline in healthy volunteers. Confidential report 67l4/649i

    Google Scholar 

  • Fujihara M, Hirakoso K, Takahashi M, Nakamura T, Harigaya S (1986 a) Biological fate of nicergoline (3). Placental transfer and mammary excretion. Oyo Yakuri (Pharmacometrics) 32: 49–56

    CAS  Google Scholar 

  • Fujihara M, Hirakoso K, Takahashi M, Nakamura T, Harigaya S (1986 b) Biological fate of nicergoline (2). Biological fate in rats and dogs after oral administration. Oyo Yakuri (Pharmacometrics) 32: 31–48

    CAS  Google Scholar 

  • Granata M, Dondero D, Tomasinelli R (1984) Studio clinico controllato della nicergolina dell’insufficienza cerebrale senile. Atti Accad Med Lomb 39: 33–40

    Google Scholar 

  • Greiner GF (1980) Therapeutische Wirkung von Nicergolin (Sermion®) im HNO-Bereich. Therapiewoche 30: 348–351

    Google Scholar 

  • Gruppo Cooperativo Italiano per lo Studio Della Nicergolina (1985) Attivita della nicergolina nel deterioramento cerebrale senile: ricerche cliniche controlatte verso placebo. Giorn Geront [Suppl] 62: 27–43

    Google Scholar 

  • Heitz C, Descombesj J, Miller RC, Steclet JC (1986) Alpha-adrenoceptor antagonistic and calcium antagonistic effects of nicergoline in the rat isolated aorta. Eur J Pharmacol 123: 279–285

    Article  PubMed  CAS  Google Scholar 

  • Herrmann WM, Stephan K, Gaede K, Apeceche M (1997) A multicenter randomized double-blind study on the efficacy and safety of niceroline in patients with multi-infarct dementia. Dementia 8: 9–17

    CAS  Google Scholar 

  • Italian Cooperative Study Group (1985) Attivita della nicergolina nel deterioramento cerebrale senile. Giorn Geront 62: 27–43

    Google Scholar 

  • Iliff LD, Du Boulay GH, Marshall JR, Ross RW, Symon L (1979) Wirkung von Nicergolin auf die Gehirndurchblutung. Arzneimittelforschung/Drug Res 29: 1277–1278

    CAS  Google Scholar 

  • Jori MC, De Paolis C, Battaglia A, Ardia A, Praga C (1985) Studio controllato multinazionale: nicergolina nel trattamento sintomatologico dell’invecchiamento cerebrale patologico. Giorn Geront 33: 1185

    Google Scholar 

  • Kohlenberg-Müller K, Meier GH, Kunz K, Wauschkuhn CH, Schaffler K (1991) Vergleichende Untersuchungen zur Bioverfügbarkeit von Nicergolin aus zwei unterschiedlichen Darreichungsformen im Steady State. Arzneimittelforschung/Drug Res 41: 28 ff

    Google Scholar 

  • Kugler J (1988) Electroencephalographic and psychometric measurements during treatment of cerebral insufficiency with nicergoline and co-dergocrine mesylate. In: Kugler J, Agnoli A (eds) Ergot alkaloids and aging brain: an update on nicergoline. Proceedings International Symposium, Rome, October 1987. Excerpta Medica, pp 68–76

    Google Scholar 

  • Kuzuya F, Hayakawa M (1985) Einfluß von Nicergolin auf die Thrombozytenaggregation und Erythrozytenverformbarkeit. In: Heidrich H (Hrsg) Therapeutische Wirksamkeitsnachweise bei nootropen und vasoaktiven Substanzen: Fortschritte in der klinischen und experimentellen Nicergolin-Forschung. Springer, Berlin Heidelberg New York Tokyo, S 193

    Google Scholar 

  • Lagarde M, Guichardant M, Ghazi I, Dechavanne M (1980) Nicergoline, an anti-aggregating agent which inhibits release of arachidonic acid from human platelet phospholipids. Prostaglandins 19: 551–557

    PubMed  CAS  Google Scholar 

  • Latkowsky B et al. (1987) Experience with Sermion® in the treatment of some inner ear diseases. Symposium Polish Neurological Society (Section of Therapy), Warsaw, March 27 (Abstracts, pp 72)

    Google Scholar 

  • Le Poncin-Lafitte M, Grosdemouge C, Billon C, Rapin JR (1981) Nicergoline: deoxyglucose uptake and cerebral blood flow under hypoxia. In: Les alpha-bloquants, pharmacologie experimentale et clinique. Masson, Paris, pp 321–325

    Google Scholar 

  • Le Poncin-Lafitte M, Grosdemouge C, Duterte D, Rapin JR (1984) Simultaneous study of haemodynamic, metabolic and behavioural sequelae in a model of cerebral ischaemia in aged rats: effects of nicergoline. Gerontology 30: 109–119

    Article  PubMed  Google Scholar 

  • Maiolo AT, Bianchi Porro G, Galli C, Sessma M (1972) Effects de la nicergoline sur l’hémodynamique cérébrale et la metabolisme cérébral dans l’hypertension artérielle essentielle et l’arteriosclerose. Clin Thér 62: 239–252

    CAS  Google Scholar 

  • Martucci N, Battaglia A (1989) A review of italian studies with Nicergoline in the aging brain. Funct Neurol 4: 27–32

    Google Scholar 

  • Martucci N, Manna V, Battaglia A (1985) Eine placebokontrollierte Studie mit Nicergolin an Patienten mit organischem Hirnsyndrom, die an kochleären und vestibulären Störungen leiden. In: Heidrich H (Hrsg) Therapeutische Wirksamkeitsnachweise bei nootropen und vasoaktiven Substanzen. Springer, Berlin Heidelberg New York Tokyo, S 57–66

    Google Scholar 

  • McArthur RA, Cervini MA, Carfagna N (1993) Nicergoline reverses the learning deficits in the radial maze of aged rats. Br Assoc Psychopharmacol, Cambridge

    Google Scholar 

  • Megna C, Calabrese S, Monitillo V, Craca A, Del Prete M (1989) Nootropic and psychotropic drugs in hemiplegic patients during rehabilitation. Funct Neurol 4: 143–147

    Google Scholar 

  • Moglia A, Arrigo A (1989) Ergot derivatives in the aging brain correlation between EEG spectral analysis and clinical findings. Funct Neurol 4: 23–26

    Google Scholar 

  • Moglia A, Arrigo A, Battaglia A, Sacchetti G (1985) Correlation between computerized EEG and clinical findings in patients with senile dementia. In: Heidrich H (ed) Proof of therapeutical effectiveness of nootropic and vasoactive drugs. Springer, Berlin Heidelberg New York Tokyo, pp 45–50

    Google Scholar 

  • Moretti A, Arcari G, Pegrassi L (1979) übersicht über pharmakologische Studien mit Nicergolin. Arzneimittelforschung/Drug Res 29(II), 8a

    Google Scholar 

  • Moretti A, Carfagna N, Caccia C, Carpentieri M, Amico A, Marchi G, Trunzo F (1985) Neurochemical effects of ergoline derivatives. In: Heidrich H (ed) Proof of therapeutical effectiveness of nootropic and vasoactive drugs. Springer, Berlin Heidelberg New York Tokyo, pp 103–110

    Google Scholar 

  • Moretti A, Carfagna N, Caccia C, Carpentieri M (1988) Effects of ergolines on neurotransmitter systems in the rat brain. Arch Int Pharmacodyn 294: 33–45

    PubMed  CAS  Google Scholar 

  • Nicergoline Cooperative Study Group (1990) A double-blind randomized study of two ergot derivatives in mild to moderate dementia. Curr Ther Res 48: 597–612

    Google Scholar 

  • Pasqui AL, Mancini A (1984) Relazione sull’attivita e tollerabilita della nicergolina dell’insufficienza cerebrale senile: confronte con placebo secondo un disegno crossover. Relazione per Ministero di Sanita

    Google Scholar 

  • Paul A, Chandra P (1979) Einfluß von Nicergolin auf molekularbiologische Prozesse im Gehirn und seine Auswirkung auf die Lernfähigkeit der Ratte. (Effect of nicergoline on molecular biological processes in the brain and its effect on the learning ability of the rat.) Arzneimittelforschung/Drug Res 29: 1238–1251

    CAS  Google Scholar 

  • Pogliani E, Delia Volpe A, Ferrari R, Recalcati P, Praga C (1975) Inhibition of human platelet aggregation by oral administration of nicergoline. A double-blind study. Il Farmaco (Prat) 30: 630–640

    CAS  Google Scholar 

  • Post C (1995) Pharmacological basis for the clinical effects of nicergoline in dementia. First European Congress of Pharmacology, Milan

    Google Scholar 

  • Praga C, Tantalo V, Maragoni R (1979) Nicergolin und Thrombocytenaggregation. Drug Res 29: 1270–1276

    CAS  Google Scholar 

  • Rafelson ME, Migne J, Santonja R, Derouette JC, Robert L (1980) Effect of an alpha-blocking agent, nicergoline, on the interaction between blood platelets, elastin and endothelial cells. Biochem Pharmacol 29: 943–947

    Article  PubMed  CAS  Google Scholar 

  • Renon P, Le Mouel C (1990) Injizierbares Nicergolin bei der Behandlung cochlearer Notfälle. In: Heidrich H (Hrsg) Therapeutische Wirksamkeitsnachweise bei nootropen und vasoaktiven Substanzen. Springer, Berlin Heidelberg New York Tokyo, S 207–215

    Google Scholar 

  • Rossi AC, Carfagna N, Caccia C, Carpentieri M, Moretti A (1988) Neurochemical effects of ergoline derivatives. In: Kugler J, Agnoli A (eds) Ergot alkaloids and aging brain an update on nicergoline. Proceedings International Symposium, Rome, October 1987. Excerpta Medica, pp 16–24

    Google Scholar 

  • Rossi A, Battaglia A, Novellini R, Buonamici M, Carfagna N, Orlando N, Pamparana F (1990) Nicergoline: pharmacological properties and clinical studies in aging brain. In: Alan R (ed) Aging brain and dementia: new trends in diagnosis and therapy. Liss, New York, pp 549–576

    Google Scholar 

  • Rubegni M, Provvedi D (1984) Nicergoline nell’ insufficienza cerebrale senile. Risultati di due studi clinici controllati verso placebo. Relazione per Ministero di Sanita

    Google Scholar 

  • Saletu B (1991) Codergocrinetype drugs in the pharmacotherapyof mental and cognitive disorders in aging. Proceedings, 5th World Congress of Biological Psychiatry, Florence, June, 9–14, 1991 (Excerpta Medica International Congress Series)

    Google Scholar 

  • Saletu B, Grünberger J, Linzmayer L, Anderer P (1990a) Brain protection of nicergoline against hypoxia: EEG brain mapping and psychometry. J Neural Transm [P-D Sect] 2: 305–325

    Article  CAS  Google Scholar 

  • Saletu B, Anderer P, Grünberger J (1990b) Topographic brain mapping of EEG after acute application of ergotalkaloids in the elderly. Arch Gerontol Geriatr 11: 1–22

    Article  PubMed  CAS  Google Scholar 

  • Saletu B, Paulus E, Linzmayer L et al. (1995) Nicergoline in senile dementia of Alzheimer type and multiinfarct dementia: a double blind, placebo-controlled, clinical and EEG/ERP mapping study. Psychopharmacology 117: 385–395

    Article  PubMed  CAS  Google Scholar 

  • Shintomi K, Egon H, Tanaka T, Itakura T, Yoshimoto K, Matsamoto M, Matsuoka Y (1986) Pharmacological study of nicergoline (I). Protective effect against anoxic brain damages in animals. Folia Pharmacol Jpn 87: 445–456

    Article  CAS  Google Scholar 

  • Shintomi K, Yoshimoto K, Ogawa Y, Itakura T, Ikezawa K, Narita H, Ishizuka T, Yamaguchi I, Yamada K (1987) Pharmacological effects of nicergoline and its metabolites, decomposition products and impurities in animals. J Pharmacobiodyn 10: 35–48

    Article  PubMed  CAS  Google Scholar 

  • Split W et al. (1987) Treatment of insufficiency of the vertebro-basilar arterial system with Sermion® (Nicergolin). Symposium, Polish Neurological Society (Section of Therapy), Warsaw, March 27 (Abstracts, p 53)

    Google Scholar 

  • Turchiaro GG, Scornaienghi D (1984) Impiego della nicergolina nel trattamento dell’insufficienza cerebrale senile. Studio clinico controllato verso placebo. Relazione per Ministero di Sanita

    Google Scholar 

  • Voronina TA, Nerobkova LN, Garibova TL, Divkova M, Nikolov R, Nikolova M, Markina NV (1988) Effect of nicergoline on learning and memory. Meth Find Exp Clin Pharmacol 10: 431–435

    CAS  Google Scholar 

  • Zappoli R, Versari A, Paganini M, Arnetoli G, Battaglia A, Ardia A, Maniero A (1988) Effect of long-term nicergoline treatment on contingent negative variation activity and clinical status of patients with presenile idiopathic mental deterioration: preliminary findings. In: Kugler J, Agnoli A (eds) Ergot alkaloids and aging brain: an update on nicergoline. Proceedings, International Symposium, Rome, October 1987. Excerpta Medica, pp 72–83

    Google Scholar 

  • Zylberman MR, Fontana M, Dolce G (1988) Effects of Nicergoline on learning, mood and behaviour in hemiplegic patients undergoing rehabilitation. In: Kugler J, Agnoli A (eds) Ergot alkaloids and aging brain: an update on Nicergoline. Proceedings, International symposium. Rome, October 1987. Excerpta Medica, pp 57–63

    Google Scholar 

Download references

Authors
  1. H. Herrschaft
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinische Neurochemie, Klinik und Poliklinik für Psychiatrie und Psychotherapie, Würzburg, Bundesrepublik Deutschland

    Peter Riederer

  2. Bezirkskrankenhaus Gabersee, Wasserburg/Inn, Bundesrepublik Deutschland

    Gerd Laux

  3. Wien, Österreich

    Walter Pöldinger

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer-Verlag Wien

About this chapter

Cite this chapter

Herrschaft, H. (1999). Nicergolin. In: Riederer, P., Laux, G., Pöldinger, W. (eds) Neuro-Psychopharmaka Ein Therapie-Handbuch. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6400-6_62

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-6400-6_62

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-7315-2

  • Online ISBN: 978-3-7091-6400-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation